Cardiotoxicity of selected vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with renal cell carcinoma

HIGHLIGHTS

• who: Beata Franczyk and collaborators from the Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Zu0307eromskiego Street, Lodz, Poland have published the research work: Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma, in the Journal: Biomedicines 2023, 11, 181. of /2023/

SUMMARY

The introduction of molecular targeted agents and immunotherapies, including vascular endothelial growth factor receptor (VEGFR)-targeted molecules (e_g, tyrosine kinase inhibitors; TKI), immune checkpoint inhibitors (ICIs) and inhibitors of the mechanistic target of rapamycin (mTOR) has improved the prognosis . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.